Cargando…
The development of neutralizing antibodies against SARS-CoV-2 and their common features
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide severe coronavirus disease 2019 (COVID-19) pandemic since December 2019. There is a great demand for effective therapies for the prevention and treatment of COVID-19. Developing therapeutic neutralizing antibodies (N...
Autores principales: | Liu, Liu Daisy, Lian, Chaoyang, Yeap, Leng-Siew, Meng, Fei-Long |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7799018/ https://www.ncbi.nlm.nih.gov/pubmed/33377928 http://dx.doi.org/10.1093/jmcb/mjaa070 |
Ejemplares similares
-
Contribution of rare mutational outcomes to broadly neutralizing antibodies: Rare features of unique anti-viral antibodies
por: Feng, Anqi, et al.
Publicado: (2022) -
Repeated vaccination of inactivated SARS-CoV-2 vaccine dampens neutralizing antibodies against Omicron variants in breakthrough infection
por: Gao, Bo, et al.
Publicado: (2023) -
Sensitivity and specificity of SARS-CoV-2 S1 subunit in COVID-19 serology assays
por: Tian, Ying, et al.
Publicado: (2020) -
Neutralizing and enhancing antibodies against SARS-CoV-2
por: Liu, Yafei, et al.
Publicado: (2022) -
Inactivated Vaccines Against SARS-CoV-2: Neutralizing Antibody Titers in Vaccine Recipients
por: Zhang, Haiying, et al.
Publicado: (2022)